1246213-45-5 Usage
Description
Carbonic acid 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]amino]-2,4-bis(1,1-dimethylethyl)phenyl methyl ester, also known as N-[5-(Methoxycarbonyloxy)-2,4-di(tert-butyl)phenyl]-4-oxo-1H-quinoline-3-carboxamide, is a chemical compound that serves as an intermediate in the synthesis of Ivacaftor (4-tertbutyl-d9) (Major) (I940603). Carbonic acid 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]amino]-2,4-bis(1,1-dimethylethyl)phenyl methyl ester is characterized by its complex molecular structure, which includes a quinolinyl carbonyl group, a carboxylic acid ester, and a di-tert-butyl phenyl group.
Uses
Used in Pharmaceutical Industry:
Carbonic acid 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]amino]-2,4-bis(1,1-dimethylethyl)phenyl methyl ester is used as an intermediate in the synthesis of Ivacaftor (4-tertbutyl-d9) (Major) (I940603) for the treatment of cystic fibrosis. Its role in the synthesis process is crucial, as it contributes to the development of a drug that can help manage the symptoms and improve the quality of life for patients with this genetic disorder.
Ivacaftor (4-tertbutyl-d9) (Major) is an isotopically labelled form of Ivacaftor (I940600), which is specifically designed to target and treat cystic fibrosis. The compound works by enhancing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for regulating the movement of salt and water in and out of cells. In patients with cystic fibrosis, this protein is either absent or dysfunctional, leading to the buildup of thick, sticky mucus in the lungs and other organs. By improving the function of the CFTR protein, Ivacaftor (4-tertbutyl-d9) (Major) can help alleviate some of the symptoms associated with the disease, such as difficulty breathing and recurrent lung infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1246213-45-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,6,2,1 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1246213-45:
(9*1)+(8*2)+(7*4)+(6*6)+(5*2)+(4*1)+(3*3)+(2*4)+(1*5)=125
125 % 10 = 5
So 1246213-45-5 is a valid CAS Registry Number.
1246213-45-5Relevant articles and documents
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
-
, (2021/04/21)
The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR
-
, (2018/01/17)
The present disclosed an improved process for the synthesis of ivacaftor starting from indole acetic acid ester which can be performed in batch as well as continuous flow synthesis. The present invention further disclosed to a continuous process for the synthesis of compound of formula (II) or formula (III) from compound of formula (I) in continuous flow reactor.
CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Paragraph 0444-0445, (2016/05/02)
The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.
